100+ Free ABPath Cytopathology Practice Questions

The ABPath Cytopathology subspecialty exam is a board certification administered by the American Board of Pathology for pathologists with advanced training in cytopathology. It validates expertise in gynecologic cytology (Pap/HPV), non-gynecologic cytology (body fluids, respiratory, urinary, CNS), and fine needle aspiration (thyroid, salivary, pancreas, breast, lymph node, soft tissue). The exam tests both morphology and clinical management using standardized reporting systems (Bethesda 2023, TBSRTC 3rd ed, Milan, Paris, IAC).

The exam is a one-day, computer-based examination with 290 total questions — 220 Written/Practical questions in 4 hours 4 minutes plus 70 Virtual Microscopy questions in 3 hours 48 minutes. All questions are multiple-choice, single-best-answer format. There are no glass slides; microscopy is performed via digital whole-slide images (virtual microscopy). The 2026 exam window runs September 8 – September 28, 2026 at Pearson VUE test centers.

The exam uses a criterion-referenced passing standard set by the Cytopathology Test Committee via a modified Angoff standard-setting process. Score reports provide pass/fail plus diagnostic performance by content domain. Historical first-time pass rates at ABPath subspecialty exams are approximately 80-90% for Cytopathology.

Candidates must (1) hold ABPath primary certification in Anatomic Pathology (AP) or AP/Clinical Pathology (AP/CP); (2) successfully complete an ACGME-accredited Cytopathology fellowship of at least 12 months; and (3) maintain an active, unrestricted medical or osteopathic license. Applications are accepted February 16 – May 15, 2026 for the Fall 2026 administration, with exam scheduling via Pearson VUE opening in July 2026.

The 2026 ABPath subspecialty certification fee is $2,100, which includes a non-refundable $200 administrative fee. Candidates who fail must reapply and pay the full fee again for the next annual cycle. The application window is February 16 – May 15, 2026. Pearson VUE may charge separate test-center fees in some regions.

Non-gyn/FNA (50%) dominates — master TBSRTC 3rd edition thyroid categories and risk of malignancy (ROM) for each (Bethesda II 0-3%, III 13-30%, IV 23-34%, V 67-83%, VI 97-99%), Milan salivary categories and ROM, Paris urinary 2022 (atypical urothelial cells: 15-40% high-grade urothelial carcinoma risk), pancreas WHO/Papanicolaou Society, and IAC serous fluid 5-category. Gynecologic (30%) requires Bethesda 2023 mastery (ASC-US HPV triage, LSIL, ASC-H, HSIL, AGC with endometrial workup in women >45), adequacy criteria, and ASCCP 2020 risk-based management. Ancillary studies (10%) include TTF-1/napsin, p40, GATA3, PAX8, calretinin, BAP1 for mesothelioma vs adenocarcinoma.

The Bethesda 2023 update (4th edition) retains the core categories (NILM, ASC-US, LSIL, ASC-H, HSIL, AGC, SCC, adenocarcinoma) but provides updated language for HPV-based screening (primary HPV, cotesting, and reflex testing), integrates LAST/WHO terminology (LSIL=CIN1, HSIL=CIN2/3), refines adequacy criteria, and incorporates ASCCP 2020 risk-based management thresholds (immediate CIN3+ risk ≥4% = colposcopy). It emphasizes risk-based rather than cytology-result-based follow-up.

Use a 6-9 month structured plan. Start with gynecologic cytology mastery (Bethesda 2023 categories, adequacy, ASCCP 2020 management). Move to thyroid Bethesda TBSRTC 3rd edition with ROM for each category, then salivary Milan, urinary Paris, IAC serous fluid, WHO pancreas, and IAC Yokohama breast. Cover ancillary studies (TTF-1/napsin/p40 for lung, GATA3 for urothelial/breast, PAX8 for thyroid/ovarian/renal, mesothelioma panel). Review CLIA cytology quality assurance (10% rescreen, 5-year lookback). Practice extensively with virtual microscopy cases and take at least two timed full-length practice exams.